16 citations
,
March 2013 in “JAMA Dermatology” This case study describes a 33-year-old woman with chronic myelogenous leukemia who developed nonscarring alopecia after starting nilotinib therapy, linked to perifollicular inflammation.
10 citations
,
August 2016 in “Dermatology Online Journal” This article describes cutaneous reactions including keratosis pilaris-like eruptions in a patient on nilotinib for chronic myelogenous leukemia, emphasizing the importance of accurately classifying such eruptions.
9 citations
,
May 2013 in “JAMA Dermatology” This report details a case of extensive leukotrichia induced by dasatinib in a patient with refractory chronic myelogenous leukemia.
19 citations
,
April 2016 in “Case Reports in Dermatology” This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.